Bicalutamide Tablet, Film Coated
Product Images NDC 47335-485

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Bicalutamide (NDC 47335-485). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bicalutamide-figure-1 (Bicalutamide Figure 1)

The text describes a figure labeled "Figure 1" that shows the probability of death for two groups receiving different antiandrogen treatments. The figure is a graph with a line graph showing the Kaplan-Meier probability of death on the y-axis and the time since trial start on the x-axis. The two groups being compared are identified as "Bicalutamide plus LHRH-A" and "Flutamide plus LHRH-A". The proportion of individuals surviving is also shown on the y-axis. The time since the start of the trial is measured in days and ranges from 0 to 1825.*

FDA Label Image

Bicalutamide-figure-2 (Bicalutamide Figure 2)

The text describes a figure labeled "Figure 2" that consists of a Kaplan-Meier curve representing the time to progression for two antiandrogen treatment groups. The proportion not progressing is shown on the y-axis ranging from 0.3 to 1.0, while the x-axis represents the days to progression ranging from 0 to 1825. The two antiandrogen treatments compared are bicalutamide plus LHRH-A and flutamide plus LHRH-A.*

FDA Label Image

Bicalutamide-structure (Bicalutamide Structure)

Not available.*

FDA Label Image

Spl Bicalutamide Tablets

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.